SGB-3383

N/A

Report date: 2025/09/25 17:45:01
NME

Base Information

Drug NameSGB-3383
Drug Alias NameSGB-3383SGB3383
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionComplement factor B inhibitors
TargetsComplement factor B
Therapy Area/IndicationsC3 glomerulopathyHematologic DiseasesAtypical Hemolytic Uremic Syndrome +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSuzhou Sanegene Bio Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSuzhou Sanegene Bio Inc
Inactive CompaniesN/A
Active IndicationsC3 glomerulopathyHematologic DiseasesAtypical Hemolytic Uremic Syndrome +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A